Free Radical Scavenging and Hepatoprotective Actions of the Medicinal Herb, Crassocephalum crepidioides from the Okinawa Islands

  • Aniya Yoko
    Laboratory of Molecular Pharmacology, Graduate School of Medicine, University of the Ryukyus
  • Koyama Tomoyuki
    Laboratory of Molecular Pharmacology, Graduate School of Medicine, University of the Ryukyus
  • Miyagi Chika
    Department of Laboratory Medicine, Faculty of Medicine, University of the Ryukyus
  • Miyahira Manami
    Laboratory of Molecular Pharmacology, Graduate School of Medicine, University of the Ryukyus
  • Inomata Chiho
    Laboratory of Molecular Pharmacology, Graduate School of Medicine, University of the Ryukyus
  • Kinoshita Shizuka
    Laboratory of Molecular Pharmacology, Graduate School of Medicine, University of the Ryukyus
  • Ichiba Toshio
    Okinawa Industrial Technology Center

この論文をさがす

抄録

Free radical scavenging and protective actions against chemically induced hepatotoxicity of Crassocephalum crepidioides were investigated. A water extract of C. crepidioides strongly scavenged superoxide anion, hydroxyl radical and also stable radical 1,1-diphenyl-2-picrylhydrazyl. Galactosamine (GalN, 400 mg/kg) and lipopolysaccharide (LPS, 0.5 μg/kg) induced hepatotoxicity of rats as seen by an elevation of serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) and of lipid peroxidation in liver homogenates was significantly depressed when the herbal extract was given intraperitoneally 1 and 15 h before GalN and LPS treatment. Similarly, carbon tetrachloride (CCl4) induced liver injury as evidenced by an increase in AST and ALT activities in serum was also inhibited by the extract pretreatment. Isochlorogenic acids, quercetin and kaempferol glycosides were identified as active components of C. crepidioides with strong free radical scavenging action. These results demonstrate that C. crepidioides is a potent antioxidant and protective against GalN plus LPS- or CCl4-induced hepatotoxicity.

収録刊行物

被引用文献 (7)*注記

もっと見る

参考文献 (45)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ